Cost of Revenue Comparison: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc.

Cost of Revenue: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, understanding cost dynamics is crucial. Over the past decade, Amphastar Pharmaceuticals, Inc. and HUTCHMED (China) Limited have showcased intriguing trends in their cost of revenue. From 2014 to 2023, Amphastar's cost of revenue surged by approximately 84%, reflecting its strategic investments and market expansion. Meanwhile, HUTCHMED's costs skyrocketed by over 430%, indicating aggressive growth and possibly higher operational expenses.

Key Insights

• Amphastar Pharmaceuticals, Inc.: Starting at 159 million in 2014, the cost of revenue reached nearly 293 million by 2023, highlighting a steady growth trajectory.
• HUTCHMED (China) Limited: From a modest 72 million in 2014, costs soared to 384 million in 2023, suggesting a rapid scale-up in operations.
  These trends underscore the diverse strategies and market conditions faced by these companies, offering valuable insights for investors and industry analysts.